For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News

BREAKING NEWS
Source: Thailand Medical News  Jan 22, 2020  4 years, 9 months, 4 weeks, 2 days, 10 hours, 28 minutes ago

Researchers Discover New Potential Drug To Prevent Liver Damage, Obesity And Glucose Intolerance

Researchers Discover New Potential Drug To Prevent Liver Damage, Obesity And Glucose Intolerance
Source: Thailand Medical News  Jan 22, 2020  4 years, 9 months, 4 weeks, 2 days, 10 hours, 28 minutes ago
A new study by researchers from Georgetown Lombardi Comprehensive Cancer Center show that animal models given a new drug targeting a key gene involved in lipid and glucose metabolism could tolerate a high-fat diet regimen (composed of 60% fat from lard) without developing significant liver damage, becoming obese, or disrupting their body's glucose balance.



Currently, the US CDC estimates that there are 4.5 million adults in the U.S. diagnosed with liver disease every year while globally the figures are about 52 million people annually. Nonalcoholic fatty liver disease, or NAFLD, can evolve to a more serious condition known as inflammatory steatohepatitis, or NASH, which can lead to chronic inflammation, scarring of the liver, and cirrhosis and eventually to hepatocellular carcinoma. While NAFLD can be reversed in the early stages with weight loss and dietetic adjustments, it becomes intractable in later stages.

To date, there is no standard therapy for NASH, albeit many drugs are being evaluated in clinical trials. Because of the now epidemic state of the liver disease, researchers at Georgetown developed a small molecule able to inhibit the activity of a key gene, Slc25a1, that they hypothesized plays an important role in fatty liver disease.

Dr Maria Laura Avantaggiati, MD, Associate Professor of Oncology at Georgetown Lombardi told Thailand Medical News, "Our research takes on a definite urgency when you consider that about 25 percent of adults in the U.S. have NAFLD. In addition, while NAFLD can be reversed with dietetic adjustments, it is difficult for these individuals to undergo dramatic life-style changes, posing a challenge to halt NAFLD evolution to NASH."

The researchers' key steps was to administer the new drug, CTPI-2, as a preventive treatment in mice fed the high-fat diet before NASH developed, or as a reversion treatment in mice with significant liver damage. This latter setting reflects what is seen people who seek medical advice when the disease is already present. The administration of CTPI-2 was able to nearly completely prevent the evolution to NASH and obesity in mice on the high-fat diet, compared to mice that did not receive the drug. At later stages of the disease, CTPI-2 also reversed liver damage, induced weight loss and restored the glucose metabolic profile.

Dr Avantaggiati added, "The results were quite dramatic as the livers of most of the mice that received CTPI-2 nearly resembled the normal livers of animals fed with a regular diet. In addition, CTPI-2 normalized glucose metabolism, leading us to hypothesize that the d rug could also have applications in the treatment of diabetes, but this aspect will need further study."

In order to confirm their findings, the investigator developed a genetically modified mouse with Slc25a1 inactivated in the liver. Mice with the inactive Slc25a1 gene were partially protected from fatty liver disease as if they were treated with CTPI-2, confirming the importance of this gene in liver damage induced by the high-fat diet.

Dr Avantaggiati further added, "We have established that CTPI-2 has anti-inflammatory activity and has anti-tumor activity towards several types of cancer. We now need to establish if CTPI-2 can also halt the progression to hepatocellular carcinoma."
 
Reference : Mingjun Tan et al, Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH, Cell Death & Differentiation (2020). DOI: 10.1038/s41418-020-0491-6
 

MOST READ

Nov 05, 2024  17 days ago
Nikhil Prasad
Jul 25, 2024  4 months ago
Nikhil Prasad
Jul 24, 2024  4 months ago
Nikhil Prasad
Jun 10, 2023  1 year ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer